EyePoint (EYPT) Total Liabilities (2011 - 2026)
EyePoint (EYPT) posted Total Liabilities of $57.7 million for Q1 2026, little changed sequentially from $57.9 million in Q4 2025, and down 10.01% YoY from $64.2 million in Q1 2025.
Analysis
EyePoint (EYPT) Total Liabilities (2011 - 2026) Analysis & Trends
EyePoint has reported Total Liabilities for 16 years, with the latest figure at $57.7 million in Q1 2026.
- Quarterly Total Liabilities fell 10.01% year-over-year to $57.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 million (down 10.01% YoY) and the FY2025 annual result came in at $57.9 million, down 29.38% from the prior year.
- Total Liabilities steadied at $57.7 million in Q1 2026 per EYPT's latest filing, from $57.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $118.4 million in Q2 2023 and troughed at $51.5 million in Q3 2025.
- A 5-year average of $78.7 million and a median of $82.0 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 44.26% in 2023, then slumped 42.53% in 2025.
- Over 5 years, Total Liabilities stood at $84.0 million in 2022, then rose by 5.8% to $88.9 million in 2023, then slipped by 7.76% to $82.0 million in 2024, then slipped by 29.38% to $57.9 million in 2025, then retreated by 0.24% to $57.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $57.7 million, $57.9 million, and $51.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 61.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.78 Mn |
| Mar 31, 2026 | 57.75 Mn |
| Dec 31, 2025 | 57.88 Mn |
| Sep 30, 2025 | 51.51 Mn |
| Jun 30, 2025 | 55.14 Mn |
| Mar 31, 2025 | 64.17 Mn |
| Dec 31, 2024 | 81.96 Mn |
| Sep 30, 2024 | 82.18 Mn |
| Jun 30, 2024 | 95.94 Mn |
| Mar 31, 2024 | 79.31 Mn |
| Dec 31, 2023 | 88.86 Mn |
| Sep 30, 2023 | 101.42 Mn |
| Jun 30, 2023 | 118.39 Mn |
| Mar 31, 2023 | 76.20 Mn |
| Dec 31, 2022 | 83.99 Mn |
| Sep 30, 2022 | 84.14 Mn |
| Jun 30, 2022 | 82.07 Mn |
| Mar 31, 2022 | 77.74 Mn |
| Dec 31, 2021 | 78.99 Mn |
| Sep 30, 2021 | 75.50 Mn |